Business development for an Alzheimer’s drug discovery company
|Coordinator||ReceptroPharma AB - ReceptorPharma/SmiLe Incubator|
|Funding from Vinnova||SEK 299 998|
|Project duration||May 2018 - August 2018|
Purpose and goal
The purposes and goals of the project have been met and we have executed the following tasks: business plan with an integrated market analysis, drug development plan up until phase 1, and the creation of a secondary screening assay. Having a validated disease-close screening assay set up within the company is value-enhancing and has made us more commercially prepared for the next step, i.e. the creation of new patentable molecules. The goal to create value in the company, both through business development and through the creation of new biological screening systems, has been met.
Expected results and effects
We have gotten the desired results from accelerating our business development and are now, from a commercial perspective, much better prepared to meet investors and strategic partners. After completed project we are now generating our own data and have a strong secondary screening assay, developed through collaboration with Lund University. The project has created secondary effects such as attracting three KOLs into our scientific board, and having been accepted into the Horizon 2020-sponsored EIT Health Smart Aging 2018 (Sep 3-Oct 26).
Planned approach and implementation
The project has been good for business related value creation. Its limited span of 3 months has generated both positives and negatives. Subcontractors have complained about our high tempo, while external parties have been attracted by our momentum. Our disposition has demanded a high workload and has been very time consuming. Dividing the project into two different types of value-enhancing activities, biology and business documents, has been more time-consuming than expected. Completion of the project has given us the results to develop the infra-structure needed going forward.